Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Deloitte
Fish and Richardson
Boehringer Ingelheim
Cerilliant
Cantor Fitzgerald
Moodys
Julphar
Colorcon

Generated: August 21, 2018

DrugPatentWatch Database Preview

Acadia Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for ACADIA PHARMS INC, and what generic alternatives to ACADIA PHARMS INC drugs are available?

ACADIA PHARMS INC has two approved drugs.

There are fifteen US patents protecting ACADIA PHARMS INC drugs.

There are one hundred and thirty patent family members on ACADIA PHARMS INC drugs in twenty-seven countries.

Summary for Acadia Pharms Inc
International Patents:130
US Patents:15
Tradenames:1
Ingredients:1
NDAs:2

Drugs and US Patents for Acadia Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Acadia Pharms Inc NUPLAZID pimavanserin tartrate CAPSULE;ORAL 210793-001 Jun 28, 2018 RX Yes Yes 6,756,393 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Acadia Pharms Inc NUPLAZID pimavanserin tartrate TABLET;ORAL 207318-001 Apr 29, 2016 RX Yes Yes 7,659,285 ➤ Try a Free Trial ➤ Try a Free Trial
Acadia Pharms Inc NUPLAZID pimavanserin tartrate TABLET;ORAL 207318-002 Jun 28, 2018 RX Yes Yes 6,815,458 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Non-Orange Book US Patents for Acadia Pharms Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,227,487 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases ➤ Try a Free Trial
8,377,959 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases ➤ Try a Free Trial
2,017,165,273 ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
McKinsey
Cerilliant
Argus Health
Dow
Moodys
Deloitte
Johnson and Johnson
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.